PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY
www.patentreply.ai/tools/patent-expiration/US11291687Important: This calculator does not include patent term extension under 35 U.S.C. § 156, which may apply to certain drug, biologic, animal drug, and medical device patents.
Learn how PTE is calculatedProcesses For Production Of Tumor Infiltrating Lymphocytes And Uses Of Same In Immunotherapy
Application No. 17480534
January 5, 2038
11y 137d remainingEarliest effective filing
Jan 5, 2018
+ 20 years
Jan 5, 2038
PTA +0d
Jan 5, 2038
TD cap (US 10420799)
Jan 5, 2038
Final
Jan 5, 2038
Filing Date
September 21, 2021
Earliest Effective Filing
January 5, 2018
Issue Date
April 5, 2022
PTA
0 days
Base Expiry (before PTA)
January 5, 2038
Processes For Production Of Tumor Infiltrating Lymphocytes And Uses Of Same In Immunotherapy
Filing Date
Sep 19, 2018
Earliest Effective Filing
Jan 5, 2018
Issue Date
Sep 24, 2019
PTA
0 days
Calculated Expiration
Jan 5, 2038
Processes For Production Of Tumor Infiltrating Lymphocytes And Uses Of Same In Immunotherapy
Filing Date
Sep 21, 2021
Earliest Effective Filing
Jan 5, 2018
Issue Date
Apr 5, 2022
PTA
0 days
Calculated Expiration
Jan 5, 2038
Processes For Production Of Tumor Infiltrating Lymphocytes And Uses Of Same In Immunotherapy
Filing Date
Jan 17, 2020
Earliest Effective Filing
Jan 5, 2018
Issue Date
May 19, 2020
PTA
0 days
Calculated Expiration
Jan 5, 2038
Processes For Production Of Tumor Infiltrating Lymphocytes And Uses Of Same In Immunotherapy
Filing Date
Dec 18, 2020
Earliest Effective Filing
Jan 5, 2018
Issue Date
May 18, 2021
PTA
0 days
Calculated Expiration
Jan 5, 2038
Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.